Because several preclinical studies and clinical trials examining FTI use in HGPS have shown many ameliorations (Gordon et al., 2014), we tested the potential use of an FTI in combination with SFN to treat HGPS cells. The gene discussed is ZMPSTE24; the disease is Hutchinson-Gilford progeria syndrome.